Intra-wound vancomycin powder reduces surgical site infection odds in spinal surgery patientsVancomycin powder may lower infection risk in spinal surgeries

This meta-analysis evaluated the impact of intra-wound vancomycin powder on surgical site infections in patients undergoing spinal surgery. The analysis included a total sample size of 9802 patients. The study aimed to determine if the local application of vancomycin powder, compared to standard intravenous prophylaxis alone, provided a measurable reduction in infection rates for spinal procedures.

The intervention group received intra-wound vancomycin powder, while the comparator group received standard intravenous prophylaxis alone. The primary outcome measured was the occurrence of overall surgical site infection. Secondary outcomes included the incidence of deep infection and superficial infection. The study design was a meta-analysis, which synthesized data from multiple studies to provide a comprehensive overview of the current evidence regarding local vancomycin application.

For the primary outcome of overall surgical site infection, the meta-analysis reported lower odds with an effect size of 0.55 (95% CI 0.44 to 0.70). When specifically analyzing randomized trials only, the result for overall surgical site infection was not statistically significant, with an effect size of 0.73 (95% CI 0.45 to 1.18). Regarding secondary outcomes, the study found lower odds for deep infection with an effect size of 0.50 (95% CI 0.37 to 0.68). Additionally, superficial infection showed lower odds with an effect size of 0.55 (95% CI 0.32 to 0.93).

Safety and tolerability data were not reported in the meta-analysis. Specific figures for adverse events, serious adverse events, or treatment discontinuations were not provided, making it impossible to determine the specific safety profile of intra-wound vancomycin powder from this data alone. The evidence for the efficacy of the intervention is characterized as having moderate certainty.

These results must be interpreted with caution because the observed association with lower infection rates was driven primarily by non-randomized studies. When the analysis was restricted to randomized trials, the findings for overall surgical site infection did not reach statistical significance. This distinction is critical for clinical interpretation, as non-randomized studies may introduce selection bias or other confounding factors that are not present in randomized controlled trials.

Methodological limitations include the heavy reliance on non-randomized data to establish the primary finding. The lack of statistical significance in the randomized trial subset suggests that the evidence base is not yet robust enough to confirm a definitive clinical benefit. Furthermore, the absence of reported safety data limits the ability to assess the risk-benefit profile of the local application compared to systemic prophylaxis.

Clinically, while intra-wound vancomycin powder is associated with fewer surgical site infections in spinal surgery, the lack of significance in randomized trials means this finding should not be used to make definitive changes to standard protocols without further high-quality evidence. The results suggest a potential benefit, but the evidence is currently insufficient to establish a clear recommendation.

Several questions remain unanswered. Specifically, the lack of reported safety data means the local tolerability of the powder is unknown. Additionally, more powered randomized trials are necessary to confirm if the observed reduction in infection rates is reproducible in a controlled setting. Until such trials are conducted, the clinical application of intra-wound vancomycin powder remains an area of moderate certainty.